Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,190,211 papers from all fields of science
Search
Sign In
Create Free Account
MS-551
Known as:
MS 551
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
nifekalant
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
Open channel block by KCB-328 [1-(2-amino-4-methanesulfonamidophenoxy)-2-[N-(3,4-dimethoxyphenethyl)-N-methylamino]ethane hydrochloride] of the heterologously expressed human ether-a-go-go-related…
Jin-bong Park
,
H. Choe
,
+6 authors
Y. Kwak
Journal of Pharmacology and Experimental…
2002
Corpus ID: 17185949
KCB-328 [1-(2-amino-4-methanesulfonamidophenoxy)-2-[N-(3,4-dimethoxyphenethyl)-N-methylamino]ethane hydrochloride] is a newly…
Expand
2001
2001
Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction.
K. Takenaka
,
S. Yasuda
,
+6 authors
H. Nonogi
Japanese circulation journal
2001
Corpus ID: 41071708
Nifekalant hydrocholoride, a novel class III antiarrhythmic agent, was used as the treatment in 4 patients with extensive…
Expand
2001
2001
Efficacy of nifekalant hydrochloride on the treatment of life-threatening ventricular tachyarrhythmias during reperfusion for acute myocardial infarction
Tomomi Koizumi
,
N. Komiyama
,
+6 authors
S. Momomura
Cardiovascular Drugs and Therapy
2001
Corpus ID: 25082767
2000
2000
QT-prolonging class I drug, disopyramide, does not aggravate but suppresses adrenaline-induced arrhythmias. Comparison with cibenzoline and pilsicainide.
S. Miyamoto
,
B. Zhu
,
T. Teramatsu
,
N. N. Aye
,
K. Hashimoto
European Journal of Pharmacology
2000
Corpus ID: 35542572
1998
1998
MS‐551 and KCB‐328, two class III drugs aggravated adrenaline‐induced arrhythmias
Yixue Xue
,
C. Yamada
,
Nu Nu Aye
,
K. Hashimoto
British Journal of Pharmacology
1998
Corpus ID: 9259587
We investigated the proarrhythmic effects of MS‐551 and KCB‐328, class III antiarrhythmic drugs using adrenaline‐induced…
Expand
1998
1998
Electrophysiologic effects of intravenous MS-551, a novel class III antiarrhythmic agent, on human atrium and ventricle.
N. Naitoh
,
K. Taneda
,
M. Tagawa
,
H. Furushima
,
M. Yamaura
,
Y. Aizawa
Japanese Heart Journal
1998
Corpus ID: 42711127
The effects of intravenous MS-551, a new class III antiarrhythmic drug, on atrium and ventricle were evaluated in 6 patients with…
Expand
1996
1996
Effects of dofetilide, a class III antiarrhythmic drug, on various ventricular arrhythmias in dogs.
Jianguang Chen
,
Yixue Xue
,
K. Eto
,
Cheng Ni
,
K. Hashimoto
Journal of Cardiovascular Pharmacology
1996
Corpus ID: 30892523
Dofetilide, a new class III antiarrhythmic agent, was tested in various kinds of canine ventricular arrhythmias to compare its…
Expand
1995
1995
MS‐551 Protects Against Ventricular Fibrillation in a Chronic Canine Model of Sudden Cardiac Death
G. Friedrichs
,
L. Chi
,
+6 authors
B. Lucchesi
Journal of Cardiovascular Pharmacology
1995
Corpus ID: 45095971
Summary We studied the electrophysiologic and anti-fibrillatory properties of MS-551 (l,3-dimethyl-6-{(2-[N-hydroxy-ethyl)-3-(4…
Expand
Highly Cited
1995
Highly Cited
1995
Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells. Different molecular mechanisms.
Katsumi Mori
,
Yukio Hara
,
Toshihiro Saito
,
Y. Masuda
,
Haruaki Nakaya
Circulation
1995
Corpus ID: 36790607
BACKGROUND It is well known that vagal stimulation increases the vulnerability to atrial fibrillation via muscarinic receptor…
Expand
1994
1994
Antiarrhythmic Agent, MS‐551, Protects Against Pinacidil + Hypoxia‐Induced Ventricular Fibrillation in Langendorff‐Perfused Rabbit Isolated Heart
G. Friedrichs
,
L. Chi
,
S. Black
,
P. J. Manley
,
B. Lucchesi
Journal of Cardiovascular Pharmacology
1994
Corpus ID: 20457578
Summary We studied the electrophysiologic and anti-fibrillatory effects of the class III agent MS-551 in a rabbit isolated heart…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE